within Pharmacolibrary.Drugs.ATC.C;

model C01CA27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 64 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0045000000000000005,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Droxidopa is a synthetic amino acid precursor of norepinephrine. It is used as a prodrug to increase norepinephrine concentrations, primarily for the treatment of neurogenic orthostatic hypotension in patients with Parkinson’s disease, multiple system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. It is currently approved for use in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for oral droxidopa use in adults with neurogenic orthostatic hypotension; general adult population with normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Chen, JJ, &amp; Hewitt, LA (2018). Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. <i>Drugs in R&amp;D</i> 18(1) 77–86. DOI:<a href=&quot;https://doi.org/10.1007/s40268-018-0226-z&quot;>10.1007/s40268-018-0226-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29392574/&quot;>https://pubmed.ncbi.nlm.nih.gov/29392574</a></p></li><li><p>Quinn, NP (1984). Anti-parkinsonian drugs today. <i>Drugs</i> 28(3) 236–262. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198428030-00002&quot;>10.2165/00003495-198428030-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6435991/&quot;>https://pubmed.ncbi.nlm.nih.gov/6435991</a></p></li><li><p>Iida, N, Tsubakihara, Y, Shirai, D, Imada, A, &amp; Suzuki, M (1994). Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 9(8) 1130–1135. DOI:<a href=&quot;https://doi.org/10.1093/ndt/9.8.1130&quot;>10.1093/ndt/9.8.1130</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7800213/&quot;>https://pubmed.ncbi.nlm.nih.gov/7800213</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01CA27;
